Sight restoring tech company launches

A biotechnology company has developed cell-based therapeutics that could potentially restore sight by replacing damaged cells in the eye caused by age-related or inherited disease.  

Tenpoint Therapeutics, which spun out of UCL in 2021, secured £57m of funding for its launch that will be used to develop a regenerative platform targeted at related cell types.  

Professor Pete Coffey, co-founder of Tenpoint Therapeutics, said: ‘We have developed a unique combination of ex vivo cell engineering where we use stem cell technology to generate new healthy cells, and in vivo reprogramming, where we built on learning from fish and amphibians that can regenerate neural cells by reprogramming structural cells in the retina.